Michelle Senchyna, PhD, provided an update of the COMET program and other development activities at Aerie Pharmaceuticals during a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.
Note: This transcript has been lightly edited for clarity.
Michelle Senchyna, VP, Clinical Development and Medical Affairs, Aerie Pharmaceuticals.
Hello everyone joining you from Eyecelerator in chilly Chicago. My name is Michelle Senchyna. I'm the vice president of Clinical Development and Medical Affairs at Aerie Pharmaceuticals. And it is my pleasure to give a brief and quick update on some of our key development activities at Aerie.
We'll start with our lead asset in the dry eye space AR-15512, which is a triple antagonist that we are developing for the treatment of signs and symptoms of dry. We have named this program the COMET program. And we are currently in phase 3. There are three COMET studies that envelop this pivotal program - two 3 months efficacy studies called COMET-2 and 3 and then a 12-month long-term safety study called COMET-4. COMET-2 and 3 are enrolling well and we expect top line data in the second half of next year. And on target is the start of the long-term safety study, which we anticipate near the end of the fourth quarter of this this year.
Then we move on to medical affairs we have an ongoing phase 4 study, an open label multicenter study with the objective of further characterizing Rocklatan and its very potent efficacy in support of its use as a first line treatment. We anticipate data from that study to roll out at the end of the first half of next year.
As always, it's my pleasure to provide updates and look forward to doing so again hopefully before the end of the year. Cheers